Study for efficacy and safety of intravitreal injection of bevacizumab (Avastin)

Study for efficacy and safety of intravitreal injection of bevacizumab (Avastin) - Study for efficacy and safety of intravitreal injection of bevacizumab (Avastin)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012248

Enrollment

Registered

2013-11-08

Start date

2012-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy central retinal vein occulusion, neovascular glaucoma

Interventions

One intravitreal injection of bevacizumab (Avastin) 2.5mg. Evaluate efficacy and safety at one month and three months after injection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: diabetic retinopathy, central retinal vein occulusion, neovascular glaucoma

Exclusion criteria

Exclusion criteria: history of ontraocular operation within one month ocular infection ocular inflammation

Design outcomes

Primary

Measure	Time frame
fundus findings	—

Countries

Japan

Contacts

Public ContactHiroko Yamazaki

National Center for Global Health and Medicine, Kohnodai Hospital Department of Ophthalmology

yamazaki@hospk.ncgm.go.jp0474848785

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026